2026-04-13T01:53:41Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/91282024-12-13T09:25:54Zcom_2072_378070com_2072_378040col_2072_378092

Analysis of histology-agnostic targets among soft tissue and bone sarcomas in the AACR GENIE database Carmagnani Pestana, Roberto Serrano Garcia, César Institut Català de la Salut [Pestana RC] Hospital Israelita Albert Einstein, São Paulo, Brazil. [Serrano C] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Sarcoma Translational Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain Vall d'Hebron Barcelona Hospital Campus Tumors de parts toves - Tractament Marcadors tumorals DISEASES::Neoplasms::Neoplasms by Site::Soft Tissue Neoplasms Other subheadings::Other subheadings::Other subheadings::/drug therapy CHEMICALS AND DRUGS::Biological Factors::Biomarkers::Biomarkers, Tumor ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de los tejidos blandos Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores::marcadores tumorales Precision medicine; Sarcoma; Tissue-agnostic biomarker Medicina de precisió; Sarcoma; Biomarcador agnòstic dels teixits Medicina de precisión; Sarcoma; Biomarcador agnóstico de tejido Background: The development of novel therapies for patients with sarcoma is challenging due to the rarity and diversity of these mesenchymal neoplasms. Hence, histology-agnostic approvals can be of particular interest for the treatment of patients with soft tissue and bone sarcoma. Methods: We queried the American Association for Cancer Research (AACR) Project Genomics Evidence Neoplasia Information Exchange (GENIE) database Cohort v12.0-Public to investigate the prevalence of currently Food and Drug Administration (FDA)-approved and other potentially actionable histology-agnostic alterations in patients with soft tissue and bone sarcoma. Targets were identified by a literature review by the authors. Results are presented for each cohort identified in the GENIE database, namely: (1) soft tissue sarcoma (STS), (2) gastrointestinal stromal tumor (GIST), (3) bone sarcoma, (4) uterine sarcoma, and (5) breast sarcoma. Results: We identified 7,512 samples of 6,955 patients with sarcoma in the AAACR GENIE database v12.0-Public. Molecular alterations that could lead to the clinical use of a currently approved histology-agnostic therapy were identified in 2.1% of sarcomas (2.6% STS, 1.3% GIST, 1.4% bone, 2.7% uterine, and 0% breast). In addition, 2.9% of patients could be eligible for future histology-agnostic approvals. These specific mutations, fusions, and amplifications occurred in multiple histotypes in all cohorts. Discussion: Exploring a public large-scale genomic database, we identified that 5% of patients with sarcoma could be eligible for current histology-agnostic FDA-approved drugs or future potential histology-agnostic indications. These actionable alterations were present in a wide variety of histologies in soft tissue and bone sarcomas, highlighting that next-generation sequencing can be considered for patients with advanced sarcoma to guide treatment strategies. 2023-03-08T13:24:45Z 2023-03-08T13:24:45Z 2023-01-18 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Pestana RC, Serrano C. Analysis of histology-agnostic targets among soft tissue and bone sarcomas in the AACR GENIE database. Front Oncol. 2023 Jan 18;12:1079909. 2234-943X https://hdl.handle.net/11351/9128 10.3389/fonc.2022.1079909 36741731 000922398300001 http://hdl.handle.net/11351/9128 eng Frontiers in Oncology;12 https://doi.org/10.3389/fonc.2022.1079909 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess application/pdf Frontiers Media Scientia